You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Dose-ranging safety and efficacy studies to advance novel mechanism-of-action small molecule leads to treat obesity-linked type 2 diabetes

    SBC: RIDGELINE THERAPEUTICS LLC            Topic: NIDDK

    ABSTRACTA staggeringof US adults are obeseSince obesity greatly dysregulates glucose homeostasisalmost all obese individuals suffer from TypediabetesT Dor prediabetesThese diseasesand accompanying comorbid chronic health complicationsare largely responsible for burgeoning US healthcare costsUnfortunatelylife style modification programstypically the first line treatment for obesity linked T Drarely ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Overcoming anti-PD-1 resistance by systemic delivery of an oncolytic adenovirus that targets TGF-beta

    SBC: Multivir Inc.            Topic: 102

    Project Summary The overall goal of this proposal is to test a novel systemic Adenoviral therapy that targets transforming growth factorTGFand reverses anti PDresistance to treat advanced breast and lung cancersThis STTR grant application illustrates the synergistic relationship between DrPrem Sethinventor of a novel TGFdecoyand MultiVir Inca leader in clinical development of gene based therapeuti ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Rapid Development of a Highly Specific Dengue Diagnostic Test

    SBC: Z-Quick, LLC            Topic: NIAID

    Project Summary Abstract The advent of the Zika virusZIKVepidemic around the world has and will cause problems for the correct diagnosis of flavivirus infectionsFor many yearsDENV serological diagnosis was relatively straightforwardHoweverafter the recent ZIKV epidemiccross reactive antibodiesAbsgenerated after ZIKV infection will bind to DENV even if the patient has never had DENVThe only FDA app ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Rapid development of a Zika-specific diagnostic test

    SBC: Z-Quick, LLC            Topic: NIAID

    Project Summary Abstract Miami has emerged as the US epicenter of the now global Zika virusZIKVepidemicThe consequences of infection remain to be fully elucidatedbut the probable link between ZIKV infection and fetal developmental complications raises enormous concern as to the potential impact of ZIKVCurrent emergency use authorizationEUAcommercial assays detect ZIKV RNAthe presence of ZIKV speci ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  5. DR?1-MOG as a Next-Generation Immunotherapy for Methamphetamine Use Disorder

    SBC: VIROGENOMICS BIODEVELOPMENT INC            Topic: R41

    Methamphetamine use disorder is associated with damage to regions of the brain that control cognitive and psychiatric functionOne third to one half of adults with methamphetamine use disorder experience cognitive impairments and other psychiatric symptoms that significantly impact treatment outcomesincreased relapse and lower treatment retention ratesMounting evidence demonstrates how immune facto ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Enhancing Clinical Therapy for wet Age-related Macular Degeneration (wetAMD)

    SBC: NANOHYBRIDS INC            Topic: N

    ABSTRACTThe wet form of age related macular degenerationAMDaccounts forof all AMD related blindness and affectsmillion people withnew cases each year in the USMinimally invasive and selective drug delivery to the eye still remains an open challengethe current standard of care involves delivery of antivascular endothelial growth factoranti VEGFdrugs via intraocular injectionFor patients refractory ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  7. Granulocyte/Monocyte Precursors to Treat Neutropenia after Cancer Chemotherapy

    SBC: CORD BLOOD PLUS, INC.            Topic: 102

    PROJECT SUMMARY ABSTRACT The objective of this proposal is to move our product forward toward commercialization by improving the quality of life for breast cancer chemotherapy patientsThis will be achieved by the following Specific AimsAimwill optimize differentiation of GMPs and neutrophil lineages in culture in response to G CSFThis will be assessed by flow cytometry to quantify production of ne ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. The anti-tumorigenic and anti-metastatic potential of Eya phosphatase inhibitors

    SBC: SIXONE SOLUTIONS, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): Breast cancer is expected to cause 39,510 deaths of American women in 2012 and 450,000 deaths globally. Once breast cancer has spread, it is essentially incurable. A critical barrier to treating advanced breast cancer is the lack of cancer-specific drugs that are effective in a large percentage of cancer patients and have low toxicity. Sixone Solutions, LLC pro ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  9. Advance Early Detection of Lupus Nephritis with ClearGold

    SBC: CLEARNANO INC            Topic: 400

    SummarySystemic lupus erythematosusSLEor lupus is an autoimmune disease that impacts more thanmillion people worldwideincludingmillion AmericansNearlyof these patients will develop lupus nephritiswhich can cause kidney failureAs a resultits financial burden to individual patient can reach $yearmuch higher than many other diseases because of kidney transplantationAlthough early treatment of lupus n ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Novel Immuno-oncology Strategy for Targeted Cytotoxic Lymphocyte Activation

    SBC: Courier Therapeutics Inc            Topic: 102

    PROJECT SUMMARY ABSTRACT Systemic administration of high dose ILhas been used since thes as an FDA approved immunotherapy for metastatic cancerDespite the fact that up toof patients treated with high dose ILachieve a durablelong term responsethis therapy is rarely used today due to significant life threatening complicationsSuch complications occur due to ILactivation of vascular endotheliumresulti ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government